Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/178—Syringes
  • A61M5/31—Details
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/178—Syringes
  • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/178—Syringes
  • A61M5/31—Details
  • A61M5/3129—Syringe barrels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/178—Syringes
  • A61M5/31—Details
  • A61M2005/3125—Details specific display means, e.g. to indicate dose setting
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/178—Syringes
  • A61M5/31—Details
  • A61M2005/3125—Details specific display means, e.g. to indicate dose setting
  • A61M2005/3126—Specific display means related to dosing
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2205/00—General characteristics of the apparatus
  • A61M2205/19—Constructional features of carpules, syringes or blisters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2205/00—General characteristics of the apparatus
  • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
  • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2205/00—General characteristics of the apparatus
  • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
  • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
  • A61M2205/585—Means for facilitating use, e.g. by people with impaired vision by visual feedback having magnification means, e.g. magnifying glasses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2207/00—Methods of manufacture, assembly or production
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
  • A61M5/142—Pressure infusion, e.g. using pumps

Definitions

• the present invention is directed to a housing for a drug delivery device.
• the invention further refers to a pen-type injector having such a housing.
• the housing may comprise an outer shell with an aperture, an insert received within the aperture and an additional member attached to the outer shell.
• the additional member is a clamp which is snapped in place or locked within the outer shell.
• a housing may be any exterior housing, like a main housing or body, or any interior housing, like an insert or an inner body.
• the housing is designed to enable safe, correct and
• the housing is designed to house, fix, protect, guide and/or engage with any of the inner components of the drug delivery device, like a drive mechanism, a cartridge, a plunger, a piston rod or the like, by limiting the exposure to contaminants, such as liquid, dust, dirt etc.
• the housing may be unitary or a multipart component of tubular or non-tubular shape.
• the exterior housing serves to house a cartridge from which a number of doses of a medicinal product may be dispensed.
• a drug delivery device with such a housing is known for example from EP 1 920 794 B1 .
• the housing of this known drug delivery device further comprises a window provided in an aperture of the housing.
• the lens acts to magnify the selected dose value thus improving readability. It is important to ensure that the window or lens is robustly and reliably secured to the outer housing so that it does not become dislodged, or fall out during use of the drug delivery device. Achieving such a robust connection between a window or lens component and the housing may be a technical challenge.
• One aspect of the present invention is to provide a catch or locking device for securing an insert to a housing which is preferably activated during assembly of the housing or the drug delivery device.
• a further component like a clamp, which is attached to the outer shell of the housing.
• This further component is provided with a lug or catch which engages a recess provided in the insert.
• joining of the insert within the outer shell of the housing is achieved by providing a notch or recess within the insert which is engaged by a lug or catch of a separate component which in turn is fixed to the outer shell of the housing.
• the aperture is formed on a side surface of the outer shell.
• the shape of the aperture may substantially conform to the shape of the insert.
• the aperture may form an opening that extends perpendicular or substantially perpendicular to a longitudinal axial of the outer shell and/or the housing.
• the main insertion direction for the insert may then be from a radially outward direction with regard to said longitudinal axis.
• the aperture may be a single piece opening or hole with a continuous inner wall surface.
• the aperture is not formed by assembly of two outer shell components having half-circled notches or the like that are put together to form an aperture. Instead the aperture is of closed shape.
• the further component or clamp is permanently attached to the outer shell during assembly of the drug delivery device.
• the insert further has at least one tail or catch extending beneath the outer shell or into a recess formed within the outer shell.
• the insert is held within the outer shell, while the further component (clamp) mainly serves to lock the insert in place.
• the tail or catch of the insert is attached to a further component (instead of the outer shell itself) which is preferably permanently attached to the outer shell.
• a robust connection between the insert and the outer shell may be achieved if the tail or catch of the insert is located at one side and the recess into which the lug or catch of the further component (clamp) engages is located at an opposite side of the insert.
• the insert is held from two opposite sides.
• the insert is provided with a male feature like a tail or catch and a female feature like a notch or recess to lock the insert within the aperture of the outer shell.
• the insert may be provided only with male features which engage corresponding female features of the outer shell and/or components attached to the outer shell or vice versa, i.e. the insert has only female features engaging male features of the outer shell and/or components attached thereto.
• the end or tip of the tail or catch may be grooved so that undesired movement of the insert especially in lateral direction is effectively prevented.
• the lug and/or catch of the insert and/or the further component may at least partly be elastic such that during assembly, the respective sections are given a level of pre-stress during installation thus eliminating play resulting from manufacturing tolerances.
• a typical example of an insert is a translucent or transparent window allowing a user to view the selected dose number e.g. of a number sleeve provided within the housing.
• the insert comprises a magnifying lens improving readability of the selected dose value.
• the insert may be a clip, an activating member or a tag with information, like the manufacturer's name or the name of a medicament. Further, the invention is not limited to embodiments with only one single insert.
• the rear surface of the insert (the side facing towards the interior of the outer shell) is provided with a printing or marking.
• the window aperture can be neatly and accurately defined and dose number alignment markings can also be applied.
• This arrangement has the further advantage that the printed surfaces are not exposed and so will not be scratched or abraded in use.
• the further component (clamp) which is attached to the outer shell is an inner housing component or a housing insert fixed to the outer shell.
• an inner housing engages or interacts with inner components of the drug delivery device, in particular components of the drive mechanism like a dose dial element, a display element (number sleeve), a drive member and/or a clutch member.
• the outer shell may be provided with at least one ledge or protrusion extending into the aperture to support the insert.
• the insert may rest on preferably two opposite ledges whilst the above mentioned locking mechanism mainly serves to fix the insert on the outer shell.
• at least one ledge is provided as a stepped portion or off-set provided at the edge or border of the aperture.
• the insert may be a plate-like element and/or an element having a shape that is substantially smaller in height in a direction perpendicular to the longitudinal axis of the outer shell or housing when received in the aperture than it extends in length and/or width in a plane substantially parallel to said longitudinal axis. It has been proven effective if at least the lower or rear surface of the insert facing the interior of the outer shell has a shape conforming to the interior surface of the shell in the section comprising the aperture.
• the outer shape of the insert may have a rounded contour to minimize injuries and offer an appealing haptic.
• the recess may be formed on a side surface of the insert, preferably the distal (i.e. directed to the needle end) side face.
• the side surface may extend substantially transversely with respect to the outer or front surface of the insert when the insert is received in the aperture.
• the side surface may also be characterized as the edge surface of the insert.
• the side surface may be stepped or have at least one step-like section such that the insert at least partly overlaps the edge of the aperture and is supported on the outer surface of the outer shell while also being able to be supported by the inner wall surface of the aperture and/or the further component (clamp) in lateral direction.
• a pen-type injector may include a cartridge and a housing as mentioned above, wherein the outer shell of the housing encases or protects at least partly the cartridge and/or components of the drive mechanism for setting and administering a dose from the cartridge.
• the further component (clamp) of the housing is an inner housing component located at least in part within the outer shell, wherein the drive mechanism comprises a display element, like a number sleeve, located interposed between the outer shell and the inner housing component.
• the outer shell and the inner housing component (clamp) may be provided coaxially with respect to each other and further coaxially with respect to the display element.
• the outer shell and/or the inner housing component engages or interacts with the display element and/or further components of the drive mechanism.
• the pen-type injector of the present invention may be a single-use device or a reusable device.
• the pen-type injector is a resettable injection device which allows to exchange an empty cartridge by a new cartridge and to reset the drive mechanism such that the pen-type injector may be reused for different cartridges.
• the pen-type injector and its housing may similarly be used in a device which has to be discarded if the cartridge is empty.
• the cartridge of the pen-type injector may contain a medicinal product such as a medicament.
• a medicament such as a medicament.
• the term ..medicament means a pharmaceutical formulation containing at least one pharmaceutically active compound, wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, , an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active
• the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis, wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1 ) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
• GLP-1 gluca
• Insulin analogues are for example Gly(A21 ), Arg(B31 ), Arg(B32) human insulin;
• Lys(B3) Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
• Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N- palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl- LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N- palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; ⁇ 29- ⁇ -( ⁇ - carboxyheptadecanoyl)-des(B30) human insulin and ⁇ 29- ⁇ -( ⁇ - carboxy
• Exendin-4 derivatives are for example selected from the following list of compounds:
• Exendin-4(1 - 39)-(Lys)6-NH2 or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exendin-4 derivative.
• Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed.
• Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
• Somatropine Somatropin
• Desmopressin Terlipressin
• Gonadorelin Triptorelin
• Leuprorelin Buserelin
• Nafarelin Goserelin
• a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned
• polysaccharides and/or a pharmaceutically acceptable salt thereof.
• An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
• Antibodies are globular plasma proteins (-150 kDa) that are also known as
• immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins.
• the basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
• the Ig monomer is a "Y"-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long.
• Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding.
• Each chain is composed of structural domains called Ig domains. These domains contain about 70-1 10 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two ⁇ sheets create a "sandwich" shape, held together by interactions between conserved cysteines and other charged amino acids.
• Ig heavy chain There are five types of mammalian Ig heavy chain denoted by ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
• the type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
• Distinct heavy chains differ in size and composition; a and ⁇ contain approximately 450 amino acids and ⁇ approximately 500 amino acids, while ⁇ and ⁇ have approximately 550 amino acids.
• Each heavy chain has two regions, the constant region (CH) and the variable region (VH).
• the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes.
• Heavy chains ⁇ , a and ⁇ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains ⁇ and ⁇ have a constant region composed of four immunoglobulin domains.
• the variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
• variable region of each heavy chain is approximately 1 10 amino acids long and is composed of a single Ig domain.
• immunoglobulin light chain there are two types of immunoglobulin light chain denoted by ⁇ and ⁇ .
• a light chain has two successive domains: one constant domain (CL) and one variable domain (VL).
• CL constant domain
• VL variable domain
• the approximate length of a light chain is 21 1 to 217 amino acids.
• Each antibody contains two light chains that are always identical; only one type of light chain, K or ⁇ , is present per antibody in mammals.
• variable (V) regions are responsible for binding to the antigen, i.e. for its antigen specificity.
• VL variable light
• VH variable heavy chain
• CDRs Complementarity Determining Regions
• an "antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from.
• Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab). The third fragment, similar in size but containing the carboxyl terminal half of both heavy chains with their interchain disulfide bond, is the crystalizable fragment (Fc).
• the Fc contains carbohydrates, complement-binding, and FcR-binding sites.
• Limited pepsin digestion yields a single F(ab')2 fragment containing both Fab pieces and the hinge region, including the H-H interchain disulfide bond.
• F(ab')2 is divalent for antigen binding.
• the disulfide bond of F(ab')2 may be cleaved in order to obtain Fab'.
• the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
• Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
• Acid addition salts are e.g. HCI or HBr salts.
• Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion
• R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6- C10-heteroaryl group.
• R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6- C10-heteroaryl group.
• solvates are for example hydrates.
• Figure 1 shows a perspective view of a housing according to a first embodiment
• Figure 2 shows a sectional view of the housing of Figure 1 ;
• Figure 3 shows a perspective view of an insert of the housing of Figure 1 ;
• Figure 4 shows an enlarged sectional detail of the housing of Figure 1 ; and Figure 5 shows a further enlarged sectional detail of the housing of Figure 1 .
• the housing 1 depicted in Figures 1 and 2 mainly comprises an outer shell 2, a clamp in the form of an inner housing 3 and an insert 4 in the form of a magnifying lens or window.
• the outer shell 2 is a tubular element having an aperture in the form of a long hole into which the insert 4 is placed.
• the aperture is formed into the side surface of the outer shell 2.
• the outer dimension of the insert 4 corresponds to the shape of the aperture in the outer shell 2 such that the outer shell 2 is fully closed by insert 4.
• the housing has a proximal end (right hand side in Figure 1 ) and an opposite distal end.
• the inner housing 3 is a stepped tubular element on the distal side having a collar 5 which has an outer diameter which is identical to outer diameter of the outer shell 2 such that the collar 5 of the inner housing 3 forms a section of the outer surface of housing 1 .
• the inner housing 3 further comprises an engagement area having an outer diameter which corresponds to the inner diameter of the outer shell 2 such that the engagement area 6 is received and fitted into outer shell 2.
• the engagement area 6 may be provided with a thread or bayonet features for attaching the cartridge holder to the inner housing 3.
• the engagement area 6 of the inner housing 3 further has a notch or groove which is engaged by a lug or ridge 7 provided on the inner surface of the outer shell 2 to snap the inner housing 3 into place within the outer shell 2.
• the inner housing 3 is firmly attached to the outer shell 2 such that at least any relative axial movement between the outer shell 2 and the inner housing 3 is prevented.
• the inner housing 3 further has a sleeve like portion 8 with a reduced outer diameter which thus forms an annular space between the inner surface of the outer shell 2 and the outer surface of the inner housing 3.
• the sleeve-like part of the inner housing 3 may be provided with an external thread 9 for interaction with a display element like a number sleeve 15.
• the insert 4 is shown in Figure 3 in more detail. According to an embodiment of the present invention the insert 4 is or may comprise a transparent window including a magnifying lens 10.
• the insert 4 has an elongate shape with a recess 1 1 provided on one side and a tail 12 or catch provided at an opposite side.
• the recess 1 1 is formed on a distal side surface of the insert 4.
• the tail 12 extends from the proximal side surface of the insert 3 in a direction opposite from the recess 1 1 .
• the insert 4 may be lightly detented to the outer shell 2 for assembly purposes as indicated at the free end of tail 12 and the lip 14 on the opposite side.
• insert 4 i.e. the side facing towards the interior of outer shell 2
• the tail 12 features a number of grooves formed into the tip end of the tail 12.
• the connection between insert 4 and outer shell 2 is depicted in Figures 4 and 5 in more detail. As can be taken from Figure 5, tail 12 of insert 4 engages beneath the inner surface of outer shell 2.
• a lug 13 provided at the engagement area 6 of inner housing 3 engages recess 1 1 of insert 4.
• insert 4 may be supported by ledges or protrusions (not shown) of outer shell 2 or inner housing 3.
• inner housing 3 is rigidly and permanently attached to the outer shell 2 during the assembly process of the drug delivery device.
• Insert 4 is retained within the aperture of outer shell 2. It is preferably located on ledges that extend along either side of the aperture in line with the main longitudinal axis of the device. These ledges prevent the insert from being pushed through the aperture and into outer shell 2.
• the insert has a tail feature 12 on one end that locates beneath the inner wall of outer shell 2. At the opposite end of a tail feature 12, the recess 1 1 is formed in the insert. This recess 1 1 is designed to engage with a lug feature 13 of the inner housing 3, thus creating a robustly connected subassembly.
• insert 4 may only have male retaining features which engage corresponding female features of the outer shell 2 or further housing components or the insert may only have female retaining features , which engage corresponding male features of the outer shell 2 or further housing components. Further, additional retaining features may be provided for the insert.

Landscapes

• Health & Medical Sciences (AREA)
• Vascular Medicine (AREA)
• Engineering & Computer Science (AREA)
• Anesthesiology (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Infusion, Injection, And Reservoir Apparatuses (AREA)

Priority Applications (14)

Applications Claiming Priority (4)

Publications (2)

Family

ID=49300029

Family Applications (1)

Country Status (15)

Cited By (2)

Families Citing this family (8)

Citations (12)

Family Cites Families (50)

• 2013
  • 2013-04-02 RU RU2014144315A patent/RU2651907C2/ru active
  • 2013-04-02 AU AU2013245106A patent/AU2013245106B2/en active Active
  • 2013-04-02 WO PCT/EP2013/056854 patent/WO2013149980A1/en not_active Ceased
  • 2013-04-02 BR BR112014023519-8A patent/BR112014023519B1/pt active IP Right Grant
  • 2013-04-02 ES ES13713443.3T patent/ES2670036T3/es active Active
  • 2013-04-02 US US14/389,570 patent/US10039883B2/en active Active
  • 2013-04-02 CN CN201380017500.XA patent/CN104203313B/zh active Active
  • 2013-04-02 HU HUE13713443A patent/HUE037439T2/hu unknown
  • 2013-04-02 KR KR1020147028985A patent/KR102124660B1/ko active Active
  • 2013-04-02 MX MX2014011989A patent/MX360468B/es active IP Right Grant
  • 2013-04-02 JP JP2015503846A patent/JP6203247B2/ja active Active
  • 2013-04-02 DK DK13713443.3T patent/DK2833947T3/en active
  • 2013-04-02 PL PL13713443T patent/PL2833947T3/pl unknown
  • 2013-04-02 TR TR2018/07046T patent/TR201807046T4/tr unknown
  • 2013-04-02 EP EP13713443.3A patent/EP2833947B1/en active Active

Patent Citations (12)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events